How do we implement ANNEXXa-I into our Clinical Practice?

November 30, 2023
For acute care physicians, anticoagulated patients presenting with intracranial hemorrhage (ICH) is an incredibly challenging clinical scenario. ANNEXa-I is a randomized, controlled, clinical trial which provides clinicians with important information on appropriate reversal of anticoagualtion to optimally care for these patients.
0 Comments

The Role of Real World Evidence in Driving Clinical Care for Anticoagulated Patients with Life-Threatening Bleeding

March 31, 2023
Experts in Emergency Medicine, Pharmacy, and Neurocritical Care describe the impact of real world evidence on the care of life-threatening bleeding in the anticoagulated patient. While clinical trial data remain the standard for clinicians, real world data provide important additional information on the use of a particular Repletion or Reversal therapy for these patients.
1 Comments

What Are the Barriers to Success When Implementing Care Pathways for ICH Patients?

July 12, 2022

ICH remains deadly and pathways matter but they aren't always what we need and barriers can be overcome with knowledge.

0 Comments

When Should We Consider Restarting Anticoagulation in DVT, PE and Afib Patients? What Should I Tell the Family To Be on the Look-Out for Once They Are Discharged?

February 1, 2022
When patients need anticoagulation but have had an ICH or large ischemic stroke, when do we restart anticoagulation? When, if ever, is it safe?  
0 Comments

Why Is the Extended Window Controversial and What Happened With the FDA?

September 7, 2021

Ever wonder why the FDA didn't approve the extended time window for tPA after ECASS3? Listen here to understand the discussion.

2 Comments
RSS
12
Categories
More Entries